Archives2023202220212020201920182017201620152014201320122011 January 28, 2013CNRS Confirms Lupuzor’sTM Effectiveness Read More November 20, 2012ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C. Read More November 15, 2012ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Read More October 08, 2012Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing Read More September 07, 2012ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012 Read More July 13, 2012ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 Read More July 03, 2012ImmuPharma PLC Appoints Cenkos Securities as Joint Broker Read More March 27, 2012PRELIMINARY RESULTS ANNOUNCEMENT for the year ended 31 December 2011 Read More February 29, 2012ImmuPharma PLC Appoints Head of Investor Relations Read More November 03, 2011ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA Read More October 21, 2011ImmuPharma regains Lupuzor rights from Cephalon due to Teva merger Read More 1…181920
November 20, 2012ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C. Read More
November 15, 2012ImmuPharma to Present Lupuzor Phase IIb Abstract / Clinical Paper at 2012 Annual ACR Meeting, Washington, D.C. Read More
October 08, 2012Cancer Programme IPP-204106 progresses into further clinical trials First cancer patients in new trial begin dosing Read More
September 07, 2012ImmuPharma to present at Rodman and Renshaw Annual Global Investment Conference, New York – Tuesday 11 September 2012 Read More
July 13, 2012ImmuPharma PLC Voted Best Medical Research and Development Company, Europe 2012 Read More
November 03, 2011ImmuPharma’s Lupuzor™ given approval to start phase III and Fast Track designation by the FDA Read More
